KB-0118

• Description :

  KB-0118 (BBC0115) is an orally active BET bromodomain inhibitor. KB-0118 selective binds to BRD2 and BRD4 over BRD3, with Kd values of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1. KB-0118 inhibits pro-inflammatory cytokines, including TNF, IL-1β, and IL-23a and selectively suppresses Th17 cell differentiation. KB-0118 modulates Th17-driven inflammation occurs through epigenetic suppression of BRD4, confirmed by downregulation of STAT3 and BRD4 target genes. KB-0118 has immunomodulatory effects in inflammatory bowel disease (IBD) model[1].

• Product Name Alternative :

  BBC0115

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain; Interleukin Related; STAT

• Related Pathways :

  Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Smiles :

  O=C1C(O)=C(C2=CC3=C(C=CN3)C=C2)OC4=C1C(O)=CC(O)=C4

• Molecular Formula :

  C17H11NO5

• Molecular Weight :

  309.27

• References & Citations :

  [1]Jeong YJ, et al. KB-0118, A novel BET bromodomain inhibitor, suppresses Th17-mediated inflammation in inflammatory bowel disease. Biomed Pharmacother. 2025 Apr;185:117933.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  BRD2; BRD4; IL-1; IL-23; STAT3

• CAS Number :

  [2648377-08-4]